Review for 10.1186/s12876-017-0569-x (2017)

Reviewer ’s report  
 
Title:  First clinica l experience in 14 patients treated with ADVOS: A study on feasibility, safety 
and efficacy of a new type of albumin dialysis  
 
Version: 0 Date: 06 Jul 2016 
 
Reviewer:  Gang  Qin 
 
Reviewer’s report:  
 
Huber et al. conducted this interesting study to evaluate feasibility, effectiveness and safety of 
ADVOS in  the first 14 patients ever treated with this procedure.  
 
 
Major concerns:  
 
In my opinion, this study might be better be case report rather than research article. For a 
research study, not only before -after comparison but external controls are required. The control 
group which did not receive ADVOS was lacking here. Although the authors explained the 
failure of expected randomized trials, the non -randomized controled study might be better.  
 
 
Minor concerns:  
 
Too many keywords.  
 
ACLF and secondary LF were not wel l defined.  
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the  necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
No 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.   
 
Yes 
 
Are you able to assess any statistics in the manuscript or would you recommend an 
additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further 
assessment in your comments to the  editors.  
 
I am able to assess the statistics  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Needs some language corrections before being published  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an 
organisation that may in any way gain or lose financially from the publication of this 
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose 
financially from the publication of this manuscript, either now or in the future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the 
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the  above, write 'I declare that I have no competing interests' 
below. If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests  
 
I agree to the open peer review policy of the journal. I understand that my name wil l be included 
on my report to the authors and, if the manuscript is accepted for publication, my named report 
including any attachments I upload will be posted on the website along with the authors' 
responses. I agree for my report to be made available und er an Open Access Creative Commons 
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments 
which I do not wish to be included in my named report can be included as confidential comments 
to the editors, which will not be published . 
 
I agree to the open peer review policy of the journal